Etoposide (C1383, 100 mM stock in DMSO, stored at −20°C), camptothecin (C9911, 10 mM stock in DMSO, −20°C) and hydroxyurea (H8627, freshly prepared 0.6 M stock in cell culture media) were from Sigma. AZ-20 (S7050, 10 mM stock in DMSO, −80°C) and VE821 (S8007, 10 mM stock in DMSO, −80°C) were from Selleckchem. DRB (10010302, 100 mM stock in DMSO, −20°C) was from Cayman Chemical. KU55933 (1685–5, 10 mM stock in DMSO, −20°C) was from Bio-Vision. Staurosporine (sc-3510A, 10 mM stock in DMSO, −20°C) and aphidicolin (sc-201535, 10 mM stock in DMSO, −20°C) were from Santa Cruz Biotechnology. Bleomycin sulfate (B4518, 1.32 mM stock in sterile H2O, −20°C) was from LKT Laboratories. Human recombinant TRAIL/APO2L (GF092, 0.5 μg/μL stock in sterile H2O, −20°C) was from Millipore.
Bleomycin sulfate
Manufactured by LKT Laboratories
Bleomycin sulfate is a cytotoxic agent used for research purposes. It is a white to off-white powder soluble in water. Bleomycin sulfate is commonly utilized in studies related to cell biology, oncology, and molecular biology.
Automatically generated - may contain errors
Lab products found in correlation
Hydroxyurea, by Merck Group (1 mentions)
Camptothecin, by Merck Group (1 mentions)
Ve 821, by Selleck Chemicals (1 mentions)
Ku55933, by Abcam (1 mentions)
Etoposide, by Merck Group (1 mentions)
Silencer pre designed sirna, by Thermo Fisher Scientific (1 mentions)
Doxorubicin, by Cayman Chemical (1 mentions)
Imatinib, by Enzo Life Sciences (1 mentions)
Sodium deoxycholate, by Merck Group (1 mentions)
Nu7441, by Cayman Chemical (1 mentions)
N lauroylsarcosine, by Merck Group (1 mentions)
P benzoquinone, by Merck Group (1 mentions)
Peg sod, by Merck Group (1 mentions)
Ku60019, by Santa Cruz Biotechnology (1 mentions)
Ultrapure lmp agarose, by Thermo Fisher Scientific (1 mentions)
Mitomycin c, by Bio-Techne (1 mentions)
1 2 diamino 4 5 dimethoxybenzenedihydrochloride, by Thermo Fisher Scientific (1 mentions)
L ascorbic acid, by Merck Group (1 mentions)
Proteinase k, by Merck Group (1 mentions)
4 protocols using bleomycin sulfate
1
Chemical Reagents for Cell-based Assays
2
Intranasal CHST15 siRNA Mitigates Bleomycin-Induced Lung Injury
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were anesthetized by isoflurane inhalation and were administered either 2 mg/kg bleomycin sulfate (LKT Laboratories), or saline only, intratracheally in a volume of 50 μL. A 2-μM injection (injection volume, 50 μL) of CHST15 siRNA (Silencer Pre-designed siRNA, catalog no. 4390815; Ambion) or negative control siRNA (Silencer Negative Control siRNA 1, catalog no. AM4611; Ambion) was dissolved in RNase-free water and administered intranasally after anesthetization by isoflurane inhalation on days 1, 4, 8, and 11. This protocol resulted in the creation of four groups: sham mice given negative control siRNA (sham group), bleomycin mice given vehicle (bleomycin group), bleomycin mice given negative control siRNA (cont siRNA group), and bleomycin mice treated with CHST15 siRNA (CHST15 siRNA group).
3
Bleomycin-Induced Lung Fibrosis Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Bleomycin sulfate (LKT Laboratories, Inc., Lot Number: 2599253, catalog Number: B4518) was diluted with sterile PBS, and was administered at a single dose of 5 mg/kg in the BLM group. Control mice received sterile PBS. Each group consisted of 10 mice. Following anesthesia (0.3 mg/kg medetomidine, 4.0 mg/kg midazolam and 5.0 mg/kg butorphanol) administration, all groups received 50 µL intranasal (i.n.) instillations of either BLM or PBS on 0 days. On 7 days (early time point) and 21 days (late time point) after BLM or PBS instillation, five mice from each group were sacrificed; MFTs and lung samples were immediately collected and fixed in 4% paraformaldehyde. To enhance preservation of lung architecture, the lungs were first inflated with the fixative prior to immersion in the fixative solution. Two hours before sampling, mice were i.p. injected with 5-bromodeoxycytidine (BrdU) (Wako, Osaka, Japan) diluted in 0.01 M PBS, at a dose of 50 mg/kg.
4
DNA Damage Repair Protocols
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!